Another instance where a judge blocked the launch of a generic drug pending the outcome of patent litigation: the Galderma* vs Mylan suit with respect to Oracea.
*State University of New York, Galderma’s licensor, is also a plaintiff.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”